Skip to main content

Future Therapies for the Myeloproliferative Neoplasms

Current Hematologic Malignancy Reports volume 6, pages 22–27 (2011)Cite this article

Abstract

Ever since their description as “myeloproliferative syndromes” by William Dameshek in 1951, the myeloproliferative neoplasms (MPNs) have been managed by the selective use of rather mundane, nonspecific therapies that rely on either antiplatelet effects or myelosuppression. The year 2005 ushered in a new era of drug development and discovery for the MPNs after the description of the JAK2 V617F mutation and the role this constitutively active tyrosine kinase has in MPN pathogenesis. Subsequently, multiple pharmacologic agents have begun (or are about to begin) testing for the inhibition of JAK2 in an attempt to improve the treatment of MPNs. Both primary myelofibrosis and myelofibrosis following essential thrombocythemia or polycythemia vera have been the targets of the most extensive testing of these agents to date. Responses to these oral JAK2 inhibitors have been primarily intended to reduce splenomegaly and meaningfully improve symptoms; effects on the JAK2 V617F allele burden or marrow histology are limited. Toxicities have ranged from myelosuppression to significant diarrhea. Additional agents with other mechanisms of action are also targeting JAK2, including histone deacetylase inhibitors and mTOR inhibitors. The results of preliminary trials of JAK2 inhibitors in polycythemia vera and essential thrombocythemia have been mixed but are premature. Many questions remain as to the optimal JAK2 inhibitory strategy and the full extent of the benefit of single-agent JAK2 inhibition.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al.: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937–51. This key reference addresses the WHO changes in the diagnosis of the MPNs, addressing the neoplastic nature of the illnesses and the current diagnostic criteria.

    CAS  Article  PubMed  Google Scholar 

  2. Mesa RA, Verstovsek S, Cervantes F, et al.: Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007, 31(6):737–40.

    Article  PubMed  Google Scholar 

  3. Mesa RA. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Curr Opin Hematol 2008, 15(2):121–6.

    CAS  Article  PubMed  Google Scholar 

  4. • Cervantes F, Dupriez B, Pereira A, et al.: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113(13):2895–901. This article presents the most comprehensive prognostic criteria for myelofibrosis ever published, based on high-quality analysis of over 1,000 patients.

    CAS  Article  PubMed  Google Scholar 

  5. Mesa RA, Niblack J, Wadleigh M, et al.: The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 2007, 109(1):68–76.

    Article  PubMed  Google Scholar 

  6. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al.: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007, 109(6):2446–52.

    CAS  Article  PubMed  Google Scholar 

  7. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al.: Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004 Jan 8;350(2):114–24.

    CAS  Article  PubMed  Google Scholar 

  8. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 2005 Sep;19(5):243–52.

    Article  PubMed  Google Scholar 

  9. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al.: Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007 Sep;21(9):1952–9.

    CAS  Article  PubMed  Google Scholar 

  10. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al.: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005 Jul 7;353(1):33–45.

    CAS  Article  PubMed  Google Scholar 

  11. • Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al.: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008 Oct 15;112(8):3065–72. This is the first report of molecular remission in patients with PV with the use of interferon.

    CAS  Article  PubMed  Google Scholar 

  12. Quintas-Cardama A, Kantarjian HM, Garcia-Manero G, Cortes J, Richie MA, Borthakur G, et al.: Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV) [abstract]. ASH Annual Meeting Abstracts 2008, 112(11):658.

  13. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009, 113(22):5394–400.

    CAS  Article  PubMed  Google Scholar 

  14. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009 Aug;83(2):154–5.

    CAS  Article  PubMed  Google Scholar 

  15. Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000;85(6):595–9.

    CAS  PubMed  Google Scholar 

  16. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, et al.: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101(7):2534–41.

    CAS  Article  PubMed  Google Scholar 

  17. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000 Apr 1;95(7):2226–33.

    CAS  PubMed  Google Scholar 

  18. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. British Journal of Haematology. 1998;103(2):505–11.

    CAS  Article  PubMed  Google Scholar 

  19. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, et al.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006 Aug 15;108(4):1158–64.

    CAS  Article  PubMed  Google Scholar 

  20. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005 Feb;74(2):117–20.

    CAS  Article  PubMed  Google Scholar 

  21. • Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009 Dec 17;114(26):5264–70. This is the most comprehensive prospective trial of allogeneic stem cell transplantation in myelofibrosis.

    Article  PubMed  Google Scholar 

  22. • Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al.: Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. N Engl J Med 2010, 363(12):1117–27. This is the first major report of the efficacy of a JAK2 inhibitor in patients with myelofibrosis.

    CAS  Article  PubMed  Google Scholar 

  23. Mesa RA, Verstovsek S, Kantarjian HM, Pardanani AD, Friedman S, Newton R, et al.: INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF). Blood 2008 November 16, 2008;112(11):1760–.

    Google Scholar 

  24. Mesa RA, Kantarjian H, Tefferi A, et al.: Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial [abstract]. Blood 2009, 114(22):a3917.

    Google Scholar 

  25. Pardanani AD, Jason R Gotlib M, MS, Catriona Jamieson M, PhD, Jorge Cortes M, Moshe Talpaz M, Richard Stone M, et al.: A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden [abstract]. Blood 2009, 114(22):a755.

    Google Scholar 

  26. Verstovsek S, Odenike O, Scott B, et al.: Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/Polycythemia Vera Myelofibrosis [abstract]. Blood 2009;114(22):a3905.

    Google Scholar 

  27. Hexner E, Goldberg JD, Prchal JT, et al.: A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC) [abstract]. Blood 2009, 114(22):a754.

    Google Scholar 

  28. Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, et al.: Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010, 85(2):129-30.

    CAS  PubMed  Google Scholar 

  29. Mascarenhas J, Wang X, Rodriguez A, et al.: A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) [abstract]. Blood 2009;114(22):a308.

    Google Scholar 

  30. Vannucchi AM, Guglielmelli P, Gattoni E, et al.: RAD001, an inhibitor of mTOR, shows clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF) [abstract]. Blood 2009, 114(22):a307.

    Google Scholar 

  31. Verstovsek S, Passamonti F, Rambaldi A, et al.: A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea [abstract]. Blood 2009, 114(22):a311. First report of a JAK2 inhibitor in patients with ET and PV.

    Google Scholar 

  32. Moliterno AR, Hexner E, Roboz GJ, et al.: An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients [abstract]. Blood 2009, 114(22):a753.

    Google Scholar 

  33. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al.: Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009, 27(32):5418–24.

    CAS  Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Affiliations

  1. Division of Hematology and Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, USA

    Robyn Scherber & Ruben A. Mesa

Authors
  1. Robyn Scherber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruben A. Mesa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruben A. Mesa.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Scherber, R., Mesa, R.A. Future Therapies for the Myeloproliferative Neoplasms. Curr Hematol Malig Rep 6, 22–27 (2011). https://doi.org/10.1007/s11899-010-0068-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-010-0068-4

Keywords

  • Myelofibrosis
  • Jak2 inhibitors
  • Myeloproliferative neoplasm
  • Treatment
  • Essential thrombocythemia
  • Polycythemia vera